Oncology – Urological
SR | Management of lymph node–positive penile cancer
24 May, 2023 | 13:03h | UTCManagement of Lymph Node–positive Penile Cancer: A Systematic Review – European Urology
Epidemiology of bladder cancer in 2023: a systematic review of risk factors
22 May, 2023 | 13:23h | UTCEpidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors – European Urology
RCT | Cabozantinib addition to nivolumab and ipilimumab extends progression-free survival in renal-cell carcinoma
18 May, 2023 | 13:38h | UTCCabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cabozantinib in Renal-Cell Carcinoma – NEJM Resident 360
Commentary on Twitter
Clinical Pearls & Morning Reports: Cabozantinib in Renal-Cell Carcinoma. How did the addition of cabozantinib to nivolumab and ipilimumab affect outcomes in the trial by Choueiri et al.? https://t.co/x1FzWBiasr #MedEd #MedTwitter pic.twitter.com/w4sns1ifLG
— NEJM Resident 360 (@NEJMres360) May 16, 2023
M-A | First‐line therapy for adults with advanced renal cell carcinoma
12 May, 2023 | 13:33h | UTCSummary: Initial treatment for adults with advanced kidney cancer (renal cell carcinoma) – Cochrane Library
A review of modern imaging landscape for prostate cancer: a comprehensive clinical guide
9 May, 2023 | 14:34h | UTC
RCT | Long-term survival benefit with abiraterone plus ADT in metastatic PC, but no advantage with enzalutamide association
8 May, 2023 | 13:02h | UTC
Commentary on Twitter
NEW: Final results from two randomised ph 3 trials of the STAMPEDE platform protocol suggest that enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. #pcsmhttps://t.co/P1uqzE4Wsv pic.twitter.com/l8U7DQZIoe
— The Lancet Oncology (@TheLancetOncol) May 4, 2023
21-y clinical trial update | Effects of a PSA–based screening on morbidity and mortality of prostate cancer
5 May, 2023 | 14:56h | UTC
AUA/SUO Guideline | Part I – Early detection of prostate cancer: prostate cancer screening
2 May, 2023 | 13:49h | UTC
AUA/SUO Guideline | Part II – Early detection of prostate cancer: considerations for a prostate biopsy
2 May, 2023 | 13:47h | UTC
AUA/SUO Guideline | Updates to Advanced Prostate Cancer
2 May, 2023 | 13:46h | UTCUpdates to Advanced Prostate Cancer: AUA/SUO Guideline (2023) – The Journal of Urology
AUA/SUO Guideline | Diagnosis and management of non-metastatic upper tract urothelial carcinoma
2 May, 2023 | 13:44h | UTC
Clinical trial 2y update | Avelumab first-line maintenance for advanced urothelial carcinoma
2 May, 2023 | 13:30h | UTCOriginal Article: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma – New England Journal of Medicine
Single-arm trial | Retroperitoneal lymph node dissection as first-line treatment for early metastatic seminoma shows 81% 2-Year RFS
28 Apr, 2023 | 13:02h | UTCCommentary: Retroperitoneal Lymph Node Dissection for Early Metastatic Testicular Seminoma – The ASCO Post
Review | Risk stratification of low-risk prostate cancer: individualizing care in the era of active surveillance
25 Apr, 2023 | 14:35h | UTCRisk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance – Journal of Urology (free PDF for a limited period)
Related:
Low-Value Prostate-Specific Antigen Screening in Older Males – JAMA Network Open
RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer
RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life
25 Apr, 2023 | 14:34h | UTC
M-A | 5-alpha-reductase inhibitors are not associated with increased risk of mortality from prostate cancer
24 Apr, 2023 | 13:30h | UTCAssociation Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis – JAMA Oncology (free for a limited period)
Commentary on Twitter
Systematic review & meta-analysis drawing on 2 decades of epidemiologic literature and including data from over 3 million patients shows no significant association between use of 5-alpha reductase inhibitor use and mortality from prostate cancer. https://t.co/3l9jT1l2P9 #PCSM
— JAMA Oncology (@JAMAOnc) April 21, 2023
ASCO Guideline Update | Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer
18 Apr, 2023 | 12:54h | UTC
RCT | MRI–guided vs CT–guided stereotactic body radiotherapy for prostate cancer
18 Apr, 2023 | 12:52h | UTC
RCT | Effects of focal vs. extended irreversible electroporation ablation of localized prostate cancer
12 Apr, 2023 | 13:05h | UTCEffect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary on Twitter
Irreversible electroporation (IRE) can provide promising oncological control as a focal therapy for patients with localized low-intermediate risk prostate cancer patients. https://t.co/lmYnYpSRmY
— JAMA Surgery (@JAMASurgery) February 1, 2023
Phase 2 RCT | Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer
10 Apr, 2023 | 13:41h | UTCAddition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
Randomized trial of intermittent hormone therapy +/- radiation to oligometastatic sites of #prostatecancer shows significantly improved PFS & assoc time off hormone therapy & w/normal testosterone from combination. https://t.co/ZnmkQuqHZm #RadOnc #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) April 6, 2023
ESMO Guideline | Updated treatment recommendations for prostate cancer
6 Apr, 2023 | 13:18h | UTC
Guideline | Muscle-invasive and metastatic bladder cancer
6 Apr, 2023 | 13:19h | UTCMuscle-invasive and Metastatic Bladder Cancer – European Association of Urology (see PDF)
RCT | Enzalutamide versus standard antiandrogen therapy in hormone-sensitive prostate cancer with metastasis
5 Apr, 2023 | 13:30h | UTCTestosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
News Release: ENZAMET shows promise as prostate cancer treatment – University of Adelaide
RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer
15 Mar, 2023 | 15:24h | UTCSummary: The article reports on a study that evaluated patient-reported outcomes of 1,643 participants in the ProtecT trial over a period of 7 to 12 years to assess the long-term functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring for localized prostate cancer detected by PSA screening.
The study found that generic quality-of-life scores were similar among the randomized groups over 7 to 12 years. However, although the prostatectomy group had a lower incidence of nocturia, they showed a higher incidence of urinary incontinence and sexual dysfunction compared to the radiotherapy and active monitoring groups. The radiotherapy group had a higher incidence of fecal leakage compared to the other groups.
The study provides evidence that helps patients and their clinicians assess the trade-offs between treatment harms and benefits and make better-informed treatment decisions.
Article: Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment – NEJM Evidence
Original Study: RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
Consensus Statement | Best current practice and research priorities in active surveillance for prostate cancer
15 Mar, 2023 | 15:11h | UTC